Drug Trial Radar · NCT05017116
A Single and Repeated Dose Escalation of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) Infection
Last checked: Nov 19, 2026Latest source record: Dec 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Aug 9, 2021
Primary completion
Oct 25, 2023
Study completion Oct 25, 2023
Sponsor
- Lead sponsor
- Suzhou Ribo Life Science Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, single (Part A) and repeated dose (Part B) escalation, phase I clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary pharmacodynamics (PD) of RBD1016 in subjects with chronic HBV infection.
Conditions
- Chronic Hepatitis B
Interventions
RBD1016Drug
subcutaneous injection
PlaceboDrug
subcutaneous injection
EntecavirDrug
Take orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs) and serious adverse events (SAEs) within 28 days after treatment (Part A)Time frame: up to 28 days
- Adverse events (AEs) and serious adverse events (SAEs) within 28 days after the last treatment(Part B)Time frame: up to 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The University of Hong Kong
Hong Kong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.